ALX Oncology’s (ALXO) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of ALX Oncology (NASDAQ:ALXO) in a research report sent to investors on Wednesday,Benzinga reports. HC Wainwright currently has a $25.00 target price on the stock.

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a research note on Tuesday, November 12th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $8.50.

ALX Oncology Stock Performance

Shares of ALX Oncology stock traded down $0.19 during trading on Wednesday, hitting $1.65. 798,310 shares of the stock were exchanged, compared to its average volume of 815,373. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. ALX Oncology has a 12 month low of $1.19 and a 12 month high of $17.83. The stock’s fifty day moving average is $1.49 and its 200 day moving average is $3.39. The stock has a market cap of $87.03 million, a PE ratio of -0.55 and a beta of 1.04.

Insider Buying and Selling

In other ALX Oncology news, Director Rekha Hemrajani bought 30,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was acquired at an average price of $1.55 per share, with a total value of $46,500.00. Following the completion of the transaction, the director now directly owns 33,000 shares in the company, valued at approximately $51,150. This represents a 1,000.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 33.40% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Point72 Asset Management L.P. acquired a new position in ALX Oncology in the 2nd quarter valued at approximately $1,834,000. GSA Capital Partners LLP purchased a new position in shares of ALX Oncology during the 3rd quarter valued at $88,000. Marshall Wace LLP increased its stake in shares of ALX Oncology by 423.0% in the second quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock worth $3,833,000 after acquiring an additional 514,133 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of ALX Oncology by 33.6% during the third quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock worth $50,000 after acquiring an additional 6,888 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in ALX Oncology by 394.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after purchasing an additional 5,200 shares during the last quarter. 97.97% of the stock is owned by institutional investors and hedge funds.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.